ClinicalTrials.gg
CompletedNCT00366340Updated Aug 8, 2012Results posted

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 51 sites in Germany. Open to participants aged 56 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-08.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Randomized
Ages
56 Days to 112 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given concomitantly with Infanrix hexa at 2, 3, 4, months (infant series) and at 11-12 months of age (toddler dose) in Germany.

02

Conditions studied

  • Vaccines, Pneumococcal

Keywords

  • safety
  • Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
56 Days to 112 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 2 months (56 to 112 days) at time of enrollment.
  2. Available for entire study period and whose parent(s) or legal guardian(s) could be reached by telephone.
  3. Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
  4. Parent(s) or legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria

Exclusion criteria:

  1. Previous vaccination with licensed or pneumococcal vaccine.
  2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or vaccines.
  3. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  4. to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
  5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  6. Known or suspected immune deficiency or suppression.
  7. History of culture-proven invasive disease caused by S pneumoniae or H influenzae type b.
  8. Major known congenital malformation or serious chronic disorder.
  9. Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
  10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis®).
  11. Participation in another investigational trial. Participation in purely observational studies was acceptable.
  12. Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
604 participants (actual)

Study arms

  • Experimental
    1

    13-valent pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

  • Active comparator
    2

    7-valent pneumococcal conjugate vaccine

    Biological: 7-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after 3-dose infant series (5 months of age)

  2. Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.

    Time frame: One month after 3-dose infant series (5 months of age)

  3. Percentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.

    Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after 3-dose infant series (5 months of age)

  4. Geometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after 3-dose infant series (5 months of age)

  5. Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose

    Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units \[IU\]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).

    Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)

  6. Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose

    Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)

  7. Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose

    Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)

  8. Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose

    Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)

  9. Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose

    Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: Immediately before (12 months of age) and one month after the toddler dose (13 months of age)

  10. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Day 1 through 4 after each dose

  11. Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Day 1 through 4 after each dose

  12. Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Day 1 through 4 after each dose

07

Results

Posted Aug 8, 2012

Participant flow

Participants were recruited in Germany from October 2006 to April 2007.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started301303
Vaccinated dose 1300303
Vaccinated dose 2296297
Vaccinated dose 3294293
Completed293293
Not completed810
Withdrew: Protocol violation34
Withdrew: Withdrawal by subject33
Withdrew: Adverse event02
Withdrew: Lost to follow-up11
Withdrew: Failure to return10
After the Infant Series
Participant flow — After the Infant Series
Milestone13vPnC7vPnC
Started293293
Completed290287
Not completed36
Withdrew: Parent/legal guardian request11
Withdrew: Failed to return01
Withdrew: Protocol violation22
Withdrew: Adverse event01
Withdrew: Lost to follow-up01
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started290287
Completed289286
Not completed11
Withdrew: Failed to return10
Withdrew: Parent/legal guardian request01

Outcome measures

PrimaryPercentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Percentage of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after 3-dose infant series (5 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Percentage of Participants13vPnC7vPnC
Common Serotypes-Serotype 498.2 (96.0 to 99.4)98.2 (95.9 to 99.4)
Common Serotypes-Serotype 6B77.5 (72.2 to 82.2)87.1 (82.5 to 90.8)
Common Serotypes-Serotype 9V98.6 (96.4 to 99.6)96.4 (93.5 to 98.3)
Common Serotypes-Serotype 1498.9 (96.9 to 99.8)97.5 (94.9 to 99.0)
Common Serotypes-Serotype 18C97.2 (94.5 to 98.8)98.6 (96.3 to 99.6)
Common Serotypes-Serotype 19F95.8 (92.7 to 97.8)96.0 (93.0 to 98.0)
Common Serotypes-Serotype 23F88.7 (84.5 to 92.2)89.5 (85.3 to 92.9)
Additional Serotypes-Serotype 196.1 (93.2 to 98.1)1.4 (0.4 to 3.7)
Additional Serotypes-Serotype 398.2 (95.9 to 99.4)6.3 (3.7 to 9.8)
Additional Serotypes-Serotype 593.0 (89.3 to 95.6)31.6 (25.8 to 37.8)
Additional Serotypes-Serotype 6A91.9 (88.1 to 94.8)31.6 (26.1 to 37.5)
Additional Serotypes-Serotype 7F98.6 (96.4 to 99.6)4.0 (2.0 to 7.0)
Additional Serotypes-Serotype 19A99.3 (97.5 to 99.9)79.2 (73.8 to 83.9)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -2.5 to 2.6
  • 13vPnC vs 7vPnC · Difference: -9.6 · 95% CI -16.0 to -3.3
  • 13vPnC vs 7vPnC · Difference: 2.2 · 95% CI -0.4 to 5.2
  • 13vPnC vs 7vPnC · Difference: 1.5 · 95% CI -0.9 to 4.1
  • 13vPnC vs 7vPnC · Difference: -1.4 · 95% CI -4.2 to 1.2
  • 13vPnC vs 7vPnC · Difference: -0.3 · 95% CI -3.8 to 3.3
  • 13vPnC vs 7vPnC · Difference: -0.8 · 95% CI -6.0 to 4.5
PrimaryGeometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.

Time frame:
One month after 3-dose infant series (5 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
μg/mL13vPnC7vPnC
Common Serotypes - Serotype 42.18 (1.98 to 2.40)2.99 (2.68 to 3.33)
Common Serotypes - Serotype 6B0.98 (0.84 to 1.14)1.49 (1.27 to 1.75)
Common Serotypes - Serotype 9V1.65 (1.51 to 1.80)1.96 (1.77 to 2.17)
Common Serotypes - Serotype 144.14 (3.68 to 4.66)4.61 (4.07 to 5.23)
Common Serotypes - Serotype 18C1.94 (1.76 to 2.14)2.25 (2.04 to 2.49)
Common Serotypes - Serotype 19F1.73 (1.56 to 1.92)2.86 (2.53 to 3.24)
Common Serotypes - Serotype 23F1.26 (1.11 to 1.43)1.44 (1.25 to 1.65)
Additional Serotypes - Serotype 11.83 (1.64 to 2.04)0.03 (0.02 to 0.03)
Additional Serotypes - Serotype 31.55 (1.41 to 1.72)0.05 (0.04 to 0.06)
Additional Serotypes - Serotype 51.31 (1.17 to 1.46)0.20 (0.18 to 0.23)
Additional Serotypes - Serotype 6A1.33 (1.18 to 1.49)0.23 (0.20 to 0.26)
Additional Serotypes - Serotype 7F2.59 (2.36 to 2.85)0.04 (0.04 to 0.05)
Additional Serotypes - Serotype 19A3.26 (2.97 to 3.59)0.64 (0.58 to 0.71)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.73 · 95% CI 0.63 to 0.84
  • 13vPnC vs 7vPnC · Ratio: 0.65 · 95% CI 0.52 to 0.82
  • 13vPnC vs 7vPnC · Ratio: 0.84 · 95% CI 0.74 to 0.96
  • 13vPnC vs 7vPnC · Ratio: 0.90 · 95% CI 0.76 to 1.07
  • 13vPnC vs 7vPnC · Ratio: 2.25 · 95% CI 2.04 to 2.49
  • 13vPnC vs 7vPnC · Ratio: 0.60 · 95% CI 0.51 to 0.71
  • 13vPnC vs 7vPnC · Ratio: 0.88 · 95% CI 0.73 to 1.06
PrimaryPercentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.

Percentage of Participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after 3-dose infant series (5 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Antibody Titer ≥1:8 as Measured by Opsonophagocytic Activity Assay (OPA) in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series.
Percentage of Participants13vPnC7vPnC
Common Serotypes - Serotype 4 (n=92,94)100.0 (96.1 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 6B (n=100,94)96.0 (90.1 to 98.9)98.9 (94.2 to 100.0)
Common Serotypes - Serotype 9V (n=89,89)100.0 (95.9 to 100.0)100.0 (95.9 to 100.0)
Common Serotypes - Serotype 14 (n=95,89)100.0 (96.2 to 100.0)100.0 (95.9 to 100.0)
Common Serotypes - Serotype 18C (n=100,94)100.0 (96.4 to 100.0)98.9 (94.2 to 100.0)
Common Serotypes - Serotype 19F (n=100,94)96.0 (90.1 to 98.9)93.6 (86.6 to 97.6)
Common Serotypes - Serotype 23F (n=100,93)96.0 (90.1 to 98.9)95.7 (89.4 to 98.8)
Additional Serotypes - Serotype 1 (n=100,92)93.0 (86.1 to 97.1)4.3 (1.2 to 10.8)
Additional Serotypes - Serotype 3 (n=100,94)99.0 (94.6 to 100.0)24.5 (16.2 to 34.4)
Additional Serotypes - Serotype 5 (n=100,94)99.0 (94.6 to 100.0)4.3 (1.2 to 10.5)
Additional Serotypes - Serotype 6A (n=99,93)96.0 (90.0 to 98.9)72.0 (61.8 to 80.9)
Additional Serotypes - Serotype 7F (n=99,94)100.0 (96.3 to 100.0)78.7 (69.1 to 86.5)
Additional Serotypes - Serotype 19A (n=95,94)100.00 (96.2 to 100.0)17.0 (10.1 to 26.2)
PrimaryGeometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after 3-dose infant series (5 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Antibody Titer in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
titer13vPnC7vPnC
Common Serotypes -Serotype 4 (n=92,94)1573.29 (1283.03 to 1929.21)1860.79 (1540.00 to 2248.41)
Common Serotypes - Serotype 6B (n=100,94)744.43 (556.91 to 995.11)1160.76 (921.46 to 1462.19)
Common Serotypes - Serotype 9V (n=89,89)4937.84 (3614.78 to 6745.14)5379.51 (3935.51 to 7353.34)
Common Serotypes - Serotype 14 (n=95,89)2139.65 (1570.10 to 2915.79)3345.19 (2473.27 to 4524.50)
Common Serotypes - Serotype 18C (n=100,94)1509.65 (1243.64 to 1832.56)1780.26 (1382.42 to 2292.59)
Common Serotypes - Serotype 19F (n=100,94)150.12 (116.89 to 192.81)165.69 (122.98 to 223.23)
Common Serotypes - Serotype 23F (n=100,93)1089.92 (795.20 to 1493.86)1070.83 (786.59 to 1457.78)
Additional Serotypes - Serotype 1 (n=100,92)50.21 (39.39 to 64.02)4.15 (3.99 to 4.32)
Additional Serotypes - Serotype 3 (n=100,94)250.73 (205.52 to 305.89)6.13 (5.17 to 7.28)
Additional Serotypes - Serotype 5 (n=100,94)162.02 (126.31 to 207.82)4.64 (3.96 to 5.43)
Additional Serotypes - Serotype 6A (n=99,93)1228.45 (883.49 to 1708.11)122.40 (74.09 to 202.21)
Additional Serotypes - Serotype 7F (n=99,94)11544.75 (9364.02 to 14233.34)115.45 (75.16 to 177.32)
Additional Serotypes - Serotype 19A (n=95,94)442.48 (360.53 to 543.06)6.70 (5.19 to 8.66)
PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose

Predefined Antibody Levels for Haemophilus Influenzae Type b (0.15 µg/mL or 1.0 µg/mL), for Diphtheria Toxoid (0.01 or 0.1 International units \[IU\]/mL) and for Hepatitis B (≥ 10.0 mIU/mL).

Time frame:
One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Percentage of Participants13vPnC After Infant Series7vPnC After Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Haemophilus influenzae type b 0.15 µg/mL threshold89.5 (85.2 to 92.9)86.9 (82.1 to 90.8)100.0 (98.5 to 100.0)100.0 (98.5 to 100.0)
Haemophilus influenzae type b 1.0 µg/mL threshold58.4 (52.3 to 64.4)54.0 (47.6 to 60.2)99.6 (97.8 to 100.0)97.9 (95.2 to 99.3)
Diphtheria toxoid at 0.01 IU/mL threshold100.0 (98.7 to 100.0)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)
Diphtheria toxoid at 0.1 IU/mL threshold89.7 (85.5 to 93.0)94.2 (90.6 to 96.7)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)
Hepatitis B at ≥ 10.0 mIU/mL94.9 (91.7 to 97.2)96.3 (93.2 to 98.2)99.3 (97.4 to 99.9)98.5 (96.1 to 99.6)
Statistical analysis
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 2.6 · 95% CI -3.0 to 8.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 4.5 · 95% CI -4.1 to 13.0
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.4 to 1.5
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: -4.5 · 95% CI -9.3 to 0.3
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.5 to 1.5
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: -1.3 · 95% CI -5.0 to 2.3
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 1.7 · 95% CI -0.4 to 4.4
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.8 · 95% CI -1.3 to 3.3
PrimaryGeometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Time frame:
One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
μg/mL13vPnC After Infant Series7vPnC After Infant Series13vPnC AfterToddler Dose7vPnC AfterToddler Dose
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose1.23 (1.03 to 1.46)1.00 (0.83 to 1.20)11.79 (10.36 to 13.41)10.24 (8.88 to 11.82)
Statistical analysis
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Ratio: 1.23 · 95% CI 0.96 to 1.58
  • 13vPnC AfterToddler Dose vs 7vPnC AfterToddler Dose · Ratio: 1.15 · 95% CI 0.95 to 1.39
PrimaryGeometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
Time frame:
One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
IU/mL13vPnC After Infant Series7vPnC After Infant Series13vPnC AfterToddler Dose7vPnC AfterToddler Dose
Geometric Mean Antibody Concentration of Diphtheria Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose0.36 (0.32 to 0.41)0.53 (0.47 to 0.60)2.67 (2.44 to 2.93)3.08 (2.74 to 3.47)
Statistical analysis
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Ratio: 0.68 · 95% CI 0.57 to 0.80
  • 13vPnC AfterToddler Dose vs 7vPnC AfterToddler Dose · Ratio: 0.87 · 95% CI 0.75 to 1.01
PrimaryGeometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose

Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the infant series (5 months of age) ; one month after the toddler dose (13 months of age)
Reported as:
Geometric mean · mIU/mL
Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose
mIU/mL13vPnC After Infant Series7vPnC After Infant Series13vPnC AfterToddler Dose7vPnC AfterToddler Dose
Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series and After the Toddler Dose145.19 (122.62 to 171.92)165.25 (140.33 to 194.61)1118.05 (935.26 to 1336.56)1195.82 (976.12 to 1464.98)
Statistical analysis
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Ratio: 0.88 · 95% CI 0.69 to 1.11
  • 13vPnC AfterToddler Dose vs 7vPnC AfterToddler Dose · Ratio: 0.93 · 95% CI 0.71 to 1.22
PrimaryGeometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose

Antibody concentration/geometric mean concentration as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
Immediately before (12 months of age) and one month after the toddler dose (13 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose
μg/mL13vPnC Before Toddler Dose7vPnC Before Toddler Dose13vPnC After Toddler Dose7vPnC After Toddler Dose
Common Serotypes -Serotype 4 (n=277,264,276,263)0.46 (0.42 to 0.51)0.58 (0.53 to 0.64)4.16 (3.75 to 4.62)5.07 (4.53 to 5.67)
Common Serotypes - Serotype 6B (n=275,261,273,251)0.97 (0.87 to 1.07)1.06 (0.94 to 1.20)9.14 (8.14 to 10.26)9.85 (8.66 to 11.22)
Common Serotypes - Serotype 9V (n=277,265,277,262)0.46 (0.42 to 0.50)0.52 (0.48 to 0.57)2.75 (2.52 to 2.99)3.36 (3.02 to 3.73)
Common Serotypes - Serotype 14 (n=273,263,276,260)2.20 (1.96 to 2.48)2.65 (2.34 to 3.00)8.34 (7.50 to 9.28)11.01 (9.87 to 12.29)
Common Serotypes-Serotype 18C (n=277,265,276,263)0.33 (0.30 to 0.36)0.39 (0.36 to 0.43)2.79 (2.53 to 3.07)3.44 (3.08 to 3.84)
Common Serotypes-Serotype 19F (n=276,264,276,263)0.68 (0.60 to 0.76)0.58 (0.52 to 0.66)5.99 (5.36 to 6.68)4.72 (4.12 to 5.41)
Common Serotypes-Serotype 23F (n=275,264,277,264)0.33 (0.30 to 0.37)0.39 (0.34 to 0.45)3.36 (2.98 to 3.78)4.33 (3.75 to 5.00)
Additional - Serotype 1 (n=277,264,278,257)0.52 (0.48 to 0.57)0.03 (0.02 to 0.03)4.25 (3.80 to 4.75)0.03 (0.03 to 0.04)
Additional - Serotype 3 (n=275,264,278,255)0.25 (0.23 to 0.28)0.05 (0.05 to 0.06)1.02 (0.92 to 1.13)0.07 (0.06 to 0.08)
Additional - Serotype 5 (n=275,264,276,220)0.74 (0.67 to 0.81)0.34 (0.30 to 0.39)3.56 (3.25 to 3.89)0.51 (0.45 to 0.58)
Additional - Serotype 6A (n=276,264,274,255)0.76 (0.68 to 0.85)0.33 (0.29 to 0.37)5.88 (5.24 to 6.59)1.74 (1.51 to 2.01)
Additional - Serotype 7F (n=277,264,278,263)0.99 (0.91 to 1.08)0.04 (0.04 to 0.04)4.79 (4.29 to 5.34)0.05 (0.04 to 0.05)
Additional - Serotype 19A (n=277,264,271,260)1.28 (1.14 to 1.45)0.72 (0.65 to 0.80)9.58 (8.68 to 10.58)3.79 (3.40 to 4.21)
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod)(2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Day 1 through 4 after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Tenderness-Any (n=267,267,250,241,229,221,206,96)33.032.629.231.527.121.353.451.9
Tenderness-Sig (n=260,258,236,226,215,209,176,158)7.77.04.77.54.22.910.812.7
Swelling-Any (n=266,263,244,242,226,224,190,176)28.220.526.635.126.128.636.843.8
Swelling-Mild (n=265,263,243,239,226,223,186,172)24.519.024.333.524.827.833.340.7
Swelling-Mod (n=261,256,235,227,217,211,174,158)7.35.97.76.66.95.212.112.7
Swelling-Severe(n=259,255,232,223,214,208,166,152)0.00.00.00.00.00.00.00.0
Redness-Any (n=266,272,247,252,238,231,196,184)28.236.434.446.834.939.847.456.0
Redness-Mild (n=265,271,247,250,237,229,191,180)27.236.233.645.634.238.944.552.8
Redness-Mod (n=260,256,232,224,217,210,173,158)1.91.61.73.64.62.411.615.2
Redness-Severe (n=259,255,232,222,214,208,166,153)0.00.00.00.00.00.00.00.7
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Day 1 through 4 after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)
percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 3
Fever ≥38°C but ≤ 39°C (n=269,266,248,250,242,232)43.538.746.848.446.336.6
Fever >39°C but ≤40°C (n=260,256,238,225,216,210)4.21.68.84.43.71.4
Fever >40°C (n=259,256,233,223,216,209)0.00.00.00.00.00.0
Decreased Appetite (n=269,267,249,245,236,225)33.130.333.734.333.130.2
Irritability (n=275,266,254,252,238,235)42.545.147.255.245.448.9
Increased Sleep (n=284,272,258,256,240,241)61.658.853.966.849.649.4
Decreased Sleep (n=266,264,240,234,230,221)25.226.123.823.120.924.4
Meds to Prevent Sx (n=261,262,237,234,220,220)8.89.510.115.410.015.0
Meds to Treat Sx (n=263,266,244,235,226,225)20.221.128.327.220.819.1
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Day 1 through 4 after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)
percentage of participants13vPnC Toddler Dose7vPnC Toddler Dose
Fever ≥38°C but ≤ 39°C (n=206,200)58.762.0
Fever >39°C but ≤40°C (n=174,157)12.68.9
Fever >40°C (n=166,152)0.60.0
Decreased Appetite (n=204,192)43.646.4
Irritability (n=213,200)55.461.0
Increased Sleep (n=202,197)56.454.8
Decreased Sleep (n=195,170)31.828.8
Medication to Prevent Symptoms (n=184,182)32.133.0
Medication to Treat Symptoms (n=178,167)18.018.6

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—12/300 (4%)220/299 (73.6%)
7vPnC Infant Series—10/303 (3.3%)225/300 (75%)
13vPnC Post-Infant Series—21/300 (7%)13/299 (4.3%)
7vPnC Post-Infant Series—23/303 (7.6%)25/300 (8.3%)
13vPnC Toddler Dose—3/300 (1%)152/289 (52.6%)
7vPnC Toddler Dose—4/303 (1.3%)143/284 (50.4%)
13vPnC 6-Month Follow-up—11/300 (3.7%)11/287 (3.8%)
7vPnC 6-Month Follow-up—14/303 (4.6%)8/287 (2.8%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Dose7vPnC Toddler Dose13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
BronchitisInfections and infestations2/3004/3031/3000/3030/3001/3030/3000/303
GastroenteritisInfections and infestations1/3000/3031/3004/3031/3001/3033/3003/303
Gastroenteritis rotavirusInfections and infestations2/3002/3032/3003/3031/3001/3031/3003/303
Skeletal injuryInjury, poisoning and procedural complications0/3000/3032/3003/3030/3000/3030/3002/303
DehydrationMetabolism and nutrition disorders0/3000/3030/3001/3031/3000/3032/3001/303
Febrile convulsionNervous system disorders0/3000/3031/3001/3030/3001/3030/3002/303
PyelonephritisInfections and infestations0/3000/3030/3002/3030/3000/3030/3000/303
Respiratory syncytial virus bronchiolitisInfections and infestations0/3002/3030/3000/3030/3000/3030/3000/303
Accidental exposureInjury, poisoning and procedural complications0/3000/3031/3000/3030/3000/3030/3000/303
AcidosisMetabolism and nutrition disorders0/3000/3031/3000/3030/3000/3030/3000/303
Most frequent other events
Showing 10 of 269
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Dose7vPnC Toddler Dose13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
Increased sleepGeneral disorders139/258171/256——————
Fever ≥38°C but ≤39°CGeneral disorders117/269103/266——121/206124/200——
Increased sleepGeneral disorders175/284160/272——114/202108/197——
IrritabilityGeneral disorders117/275120/266——118/213122/200——
Erythema (Any)Skin and subcutaneous tissue disorders75/26699/272——93/196103/184——
IrritabilityGeneral disorders120/254139/252——————
Tenderness (Any)Skin and subcutaneous tissue disorders88/26787/267——110/20696/185——
Erythema (Mild)Skin and subcutaneous tissue disorders72/26598/271——85/19195/180——
Increased sleepGeneral disorders119/240119/241——————
IrritabilityGeneral disorders108/238115/235——————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.5 ± 0.62.5 ± 0.62.5 ± 0.6
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female151127278
Male150176326
08

Study locations

51 sites
  • Bad Kreuznach, 55543, Germany
  • Bad Saulgau, 88348, Germany
  • Bad Sobernheim, 55566, Germany
  • Berlin, 10551, Germany
  • Berlin, 10967, Germany
  • Berlin, 13355, Germany
  • Berlin, 13409, Germany
  • Berlin, 13507, Germany
  • Berlin, 13627, Germany
  • Birkenfeld, 75217, Germany
  • Bobingen, 86399, Germany
  • Bramsche, 49565, Germany
  • Bretten, 75015, Germany
  • Cham, 93413, Germany
  • Ehingen, 89584, Germany
  • Erlangen, 91056, Germany
  • Eschwege, 37269, Germany
  • Flensburg, 24939, Germany
  • Gau-Odernheim, 55239, Germany
  • Hamburg, 22763, Germany
  • Herzogenaurach, 91074, Germany
  • Hoechberg, 97204, Germany
  • Kehl, 77694, Germany
  • Kiel, 24111, Germany
  • Kleve, 47533, Germany
  • Krefeld, 47798, Germany
  • Ludwigshafen, 67059, Germany
  • Luebeck, 23568, Germany
  • Mainz, 55101, Germany
  • Metzingen, 72555, Germany
  • Minden, 32427, Germany
  • Muenster, 48159, Germany
  • Muenster, 48165, Germany
  • Neumuenster, 24534, Germany
  • Neumünster, 24534, Germany
  • Neustadt/Aisch, 91413, Germany
  • Niebuell, 25899, Germany
  • Nuernberg, 90473, Germany
  • Nuernberg, 90482, Germany
  • Oberkirch, 77704, Germany
  • Olching, 82140, Germany
  • Pforzheim, 75172, Germany
  • Porta Westfalica, 32457, Germany
  • Ravensburg, 88214, Germany
  • Tettnang, 88069, Germany
  • Vellmar, 34246, Germany
  • Weiden, 92637, Germany
  • Weilheim, 82362, Germany
  • Welzheim, 73642, Germany
  • Wiesbaden, 65205, Germany
  • Zirndorf, 90513, Germany
09

References and documents

Publications

  • Gimenez-Sanchez F, Kieninger DM, Kueper K, Martinon-Torres F, Bernaola E, Diez-Domingo J, Steul K, Juergens C, Gurtman A, Giardina P, Liang JZ, Gruber WC, Emini EA, Scott DA; 501 and 006 study groups. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011 Aug 11;29(35):6042-8. doi: 10.1016/j.vaccine.2011.06.026. Epub 2011 Jun 23. PubMed 21704105 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2006
First posted
Aug 21, 2006
Start
Oct 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results delay requested
Feb 26, 2009
Results first posted
Aug 8, 2012
Last update
Aug 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00366340
Responsible party
Sponsor
First posted
Aug 21, 2006
Start date
Oct 2006
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Aug 8, 2012
Last update
Aug 8, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Germany, medinfoDEU@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion